Group 1 - Sensus Healthcare, Inc. (SRTS) experienced a stock increase of +2.54% to $4.44, outperforming the S&P 500's daily gain of 0.54% [1] - Prior to the recent trading session, the company's shares had declined by 8.65%, which was worse than the Medical sector's loss of 2.12% and the S&P 500's gain of 4.2% [1] Group 2 - The upcoming earnings report for Sensus Healthcare, Inc. is anticipated to show an EPS of $0.01, reflecting a 90% decline compared to the same quarter last year, with expected quarterly revenue of $8.8 million, down 4.76% year-over-year [2] - For the entire fiscal year, Zacks Consensus Estimates predict earnings of $0.11 per share and revenue of $41.95 million, indicating a decline of 73.17% in earnings and a slight increase of 0.34% in revenue from the previous year [3] Group 3 - The Zacks Rank system, which evaluates estimate revisions, currently ranks Sensus Healthcare, Inc. at 4 (Sell), with the consensus EPS estimate remaining unchanged over the past month [5] - The company's Forward P/E ratio stands at 39.36, which is significantly higher than the industry's Forward P/E of 22.47, indicating a premium valuation [6] Group 4 - The Medical - Instruments industry, to which Sensus Healthcare, Inc. belongs, has a Zacks Industry Rank of 162, placing it in the bottom 35% of over 250 industries [6][7]

Company Performance - Sensus Healthcare, Inc. closed at $4.64, reflecting a -2.11% change from the previous day, underperforming the S&P 500's daily loss of 0.11% [1] - Over the past month, shares have appreciated by 0.42%, lagging behind the Medical sector's gain of 1.66% and the S&P 500's gain of 5.17% [1] Upcoming Earnings - Analysts expect Sensus Healthcare, Inc. to report earnings of $0.01 per share, indicating a year-over-year decline of 90% [2] - The consensus estimate for revenue is $8.8 million, representing a 4.76% decline compared to the same quarter last year [2] Annual Estimates - For the annual period, the Zacks Consensus Estimates predict earnings of $0.11 per share and revenue of $41.95 million, reflecting shifts of -73.17% and +0.34% respectively from the previous year [3] - Recent changes in analyst estimates suggest evolving short-term business trends, with positive revisions indicating analyst optimism regarding business and profitability [3] Zacks Rank and Valuation - Sensus Healthcare, Inc. currently holds a Zacks Rank of 5 (Strong Sell), with the Zacks Consensus EPS estimate remaining steady over the past month [5] - The company is trading at a Forward P/E ratio of 43.09, which is a premium compared to the industry average Forward P/E of 27.15 [6] Industry Context - The Medical - Instruments industry, part of the Medical sector, has a Zacks Industry Rank of 181, placing it in the bottom 27% of over 250 industries [6] - The Zacks Industry Rank assesses the strength of industry groups based on the average Zacks Rank of individual stocks, with top-rated industries outperforming the bottom half by a factor of 2 to 1 [7]

1 in 5 Americans will develop skin cancer in their lifetime – AAD INVESTOR OVERVIEW NASDAQ: SRTS August 2024 SAFE HARBOR STATEMENT Forward-Looking Statements This presentation includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximatel ...

Core Viewpoint - Brokerage recommendations, particularly for Sensus Healthcare, Inc. (SRTS), indicate a strong buy sentiment, but reliance solely on these recommendations may not be prudent due to potential biases and misalignment with retail investors' interests [2][5][10]. Group 1: Brokerage Recommendations - Sensus Healthcare has an average brokerage recommendation (ABR) of 1.00, indicating a Strong Buy based on four recommendations, all of which are Strong Buy [2]. - Despite the strong buy recommendations, studies suggest that brokerage recommendations often fail to guide investors effectively towards stocks with high price appreciation potential [5][10]. - Analysts from brokerage firms tend to exhibit a positive bias in their ratings, with a ratio of five "Strong Buy" recommendations for every "Strong Sell" [6][10]. Group 2: Zacks Rank Comparison - The Zacks Rank, a proprietary stock rating tool, categorizes stocks from 1 (Strong Buy) to 5 (Strong Sell) and is based on earnings estimate revisions, which are more reliable indicators of near-term stock performance [8][11]. - The Zacks Rank is distinct from the ABR, as it is a quantitative model that reflects earnings estimate revisions rather than solely brokerage recommendations [9]. - The Zacks Rank is updated more frequently, providing timely insights into stock price predictions compared to the potentially outdated ABR [12]. Group 3: Earnings Estimates and Current Outlook - The Zacks Consensus Estimate for Sensus Healthcare has decreased by 61.4% over the past month to $0.11, indicating growing pessimism among analysts regarding the company's earnings prospects [13]. - This significant decline in earnings estimates has resulted in a Zacks Rank of 5 (Strong Sell) for Sensus Healthcare, suggesting caution despite the ABR indicating a buy [14].

Sensus Healthcare, Inc. (SRTS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of $0.04. This compares to earnings of $0.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -500%. A quarter ago, it was expected that this company would post earnings of $0.10 per share when it actually produced earnings of $0.09, delivering a surprise of -10%.Over the last four quarters, the company has surpa ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $8.3 million, down from $10.7 million in Q1 2024, primarily due to lower unit sales to the largest customer [13] - Gross profit for Q1 2025 was $4.4 million, resulting in a gross margin of 52% [14] - The company reported a net loss of $2.6 million or a loss of $0.16 per share compared to net income of $2.3 million or $0.14 per diluted share in the prior year quarter [17] Business Line Data and Key Metrics Changes - The company shipped 21 SRT systems in Q1 2025, bringing the total installed base to over 880 systems [4] - There was a 65% increase in patient treatments from fair deal agreement installations when comparing Q1 volumes with Q4 [8] Market Data and Key Metrics Changes - The company expects to surpass 900 systems by the end of Q2 2025 and aims to reach 1,000 units under direct sale within the next twelve months [5] - The fair deal agreement program is anticipated to contribute significantly to revenue in the second half of 2025 [10] Company Strategy and Development Direction - The company is focusing on expanding its fair deal agreement program, which aligns financial interests with patient volume and practice utilization [9] - The international strategy is progressing, with participation in major industry events and targeted marketing activities [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to profitability in each of the next three quarters and for the full year [5] - The company is strategically executing plans to build sustainable long-term growth through FDA installations and product innovation [12] Other Important Information - Operating expenses increased significantly due to strategic growth initiatives, with general and administrative expenses rising to $2.2 million from $1.6 million a year ago [15] - Research and development expenses increased to $2.6 million from $0.9 million in the prior year period, reflecting continued investment in product innovation [16] Q&A Session Summary Question: How does the first quarter of 2025 compare to the first quarter of 2024? - Management expects each subsequent quarter to be profitable, driven by revenues from fair deal agreements and product sales [22] Question: Did any part of the first quarter revenue come from the fair deal agreement? - Yes, but it was not large enough to make a significant impact [24][26] Question: Has the existing U.S. tariff policy affected business confidence? - So far, there have been no observed tariff repercussions on any of the businesses [27] Question: What is the anticipated volume once fair deal agreements are fully operational? - It typically takes four to five months from signing an agreement to initial revenue generation [31] Question: What is the current installed base and target goal by the end of 2025? - The company is not providing specific guidance on the target goal but is moving along aggressively [45] Question: What marketing support will be provided to clinics to help them reach mature utilization rates? - The company will provide analytics and aggressive marketing strategies to help clinics attract patients [46] Question: What is the expected timeline for receiving payments after treatments? - Payments are typically received between 45 and 60 days after treatments [55] Question: What is the profile of attendees at smaller conferences? - Smaller conferences attract practitioners who may not attend larger events, providing opportunities for FDA agreements [57] Question: How do the installations match up with patient databases? - The installations tend to match well with the patient data, enhancing confidence in the targeted areas for treatment [61]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $8.3 million, down from $10.7 million in Q1 2024, primarily due to lower unit sales to the largest customer [12] - Gross profit for Q1 2025 was $4.4 million, resulting in a gross margin of 52% [12] - The company reported a net loss of $2.6 million or a loss of $0.16 per share compared to net income of $2.3 million or $0.14 per diluted share in the prior year [16] Business Line Data and Key Metrics Changes - The company shipped 21 SRT systems in Q1 2025, bringing the total installed base to over 880 systems [4][5] - A 65% increase in patient treatments from fair deal agreement installations was noted when comparing Q1 volumes with Q4 [7] Market Data and Key Metrics Changes - The company expects to surpass 900 systems by the end of Q2 2025 and aims to reach 1,000 units under direct sale within the next twelve months [5] - The fair deal agreement program is anticipated to contribute significantly to revenue in the second half of 2025 [9] Company Strategy and Development Direction - The company is focusing on expanding its fair deal agreement initiative, which aligns financial interests with patient volume and practice utilization [8] - There is an ongoing strategy to enhance international presence and product innovation, particularly with the transdermal infusion system [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to profitability in each of the next three quarters and for the full year [5][17] - The company is confident in the trajectory for the remainder of 2025, particularly as FDA agreements begin to contribute to revenue [65] Other Important Information - Operating expenses increased significantly due to strategic growth initiatives, with general and administrative expenses rising to $2.2 million from $1.6 million a year ago [13] - Research and development expenses increased to $2.6 million from $0.9 million in the prior year, reflecting continued investment in product innovation [15] Q&A Session Summary Question: How does the first quarter of 2025 compare to the first quarter of 2024? - Management expects each subsequent quarter to be profitable, driven by revenues from fair deal agreements and product sales [20] Question: Did any part of the first quarter revenue come from the fair deal agreement? - Yes, but it was not large enough to significantly impact overall revenue [21][22] Question: Has the existing U.S. tariff policy affected business confidence? - So far, there have been no observed tariff repercussions on any of the businesses [24] Question: What is the anticipated volume once fair deal agreements reach full capacity? - Revenue generation typically begins four to five months after signing the agreement, with significant revenue contributions expected in the second half of 2025 [28][34] Question: What support will be provided to clinics to reach mature utilization rates? - The company plans to provide analytics and marketing support to help clinics identify and access patients [44] Question: What is the current installed base and target goal by the end of 2025? - The company is not providing specific guidance on the target goal but is moving along aggressively with existing installations [43] Question: What is the timeline for receiving payments after treatments? - Payments are typically received between 45 and 60 days after treatments occur [52]

PART I – Financial Information [Condensed Consolidated Financial Statements (unaudited)](index=4&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20(unaudited)) Q1 2025 unaudited financials report a $2.6 million net loss, decreased assets, negative operating cash flow, noting a DOJ investigation and revenue concentration [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to $60.2 million by March 31, 2025, primarily from reduced cash, with liabilities increasing and equity falling to $53.0 million Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2025 (unaudited) | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $19,072 | $22,056 | | Accounts receivable, net | $18,018 | $19,731 | | Inventories | $9,923 | $10,097 | | Total current assets | $54,196 | $56,738 | | Total assets | $60,210 | $62,165 | | **Liabilities & Equity** | | | | Total current liabilities | $6,725 | $5,885 | | Total liabilities | $7,176 | $6,338 | | Total stockholders' equity | $53,034 | $55,827 | | Total liabilities and stockholders' equity | $60,210 | $62,165 | [Condensed Consolidated Statements of Income (Loss)](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Income%20(Loss)) Q1 2025 reported a $2.57 million net loss, a shift from prior year's income, due to 21.7% lower revenues and a 188.9% increase in R&D expenses Condensed Consolidated Statements of Income (Loss) (in thousands, except per share data) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Revenues | $8,344 | $10,663 | | Gross Profit | $4,354 | $6,662 | | Total Operating Expenses | $7,000 | $3,775 | | Research and Development | $2,606 | $926 | | Income (loss) from operations | ($2,646) | $2,887 | | Net income (loss) | ($2,572) | $2,274 | | Net income (loss) per share – diluted | ($0.16) | $0.14 | [Condensed Consolidated Statements of Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders%27%20Equity) Total stockholders' equity decreased to $53.0 million by March 31, 2025, primarily due to a $2.57 million net loss and $0.3 million in stock repurchases - Key changes in stockholders' equity for Q1 2025 include a net loss of **$2.572 million** and the repurchase of stock for **$0.3 million**[18](index=18&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities was $2.7 million in Q1 2025, leading to a $3.0 million net decrease in cash, ending the quarter with $19.1 million Summary of Cash Flows (in thousands) | Activity | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($2,677) | ($8,187) | | Net cash used in investing activities | ($7) | ($233) | | Net cash used in financing activities | ($300) | $0 | | **Net decrease in cash and cash equivalents** | **($2,984)** | **($8,420)** | | Cash and cash equivalents – end of period | $19,072 | $14,728 | [Notes to the Condensed Consolidated Financial Statements (unaudited)](index=8&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements%20(unaudited)) Notes detail accounting policies, Q1 2025 revenue of $6.7 million with 69% from one customer, a $15 million credit facility, and an ongoing DOJ investigation - In 2024, the company formed Sensus Healthcare Services, LLC, a wholly owned subsidiary to provide operational healthcare services, including leased equipment and radiotherapy technologists[23](index=23&type=chunk) - A single customer in the U.S. accounted for **69%** of revenue for Q1 2025 and **87%** of accounts receivable as of March 31, 2025[41](index=41&type=chunk) - The company has a **$15 million** revolving credit facility with Comerica Bank, with no borrowings outstanding as of March 31, 2025. The facility is secured by all company assets and has several covenants[66](index=66&type=chunk)[67](index=67&type=chunk) - The company is cooperating with a Department of Justice (DOJ) investigation into the billing practices of a physician who used the company's SRT-100. The company disputes any wrongdoing and is unable to estimate the potential cost[79](index=79&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=21&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes Q1 2025's 22.4% revenue decrease to lower unit sales, with gross profit margin falling to 53.0% and operating expenses, notably R&D, significantly increasing Q1 2025 vs Q1 2024 Performance (in thousands) | Metric | Q1 2025 | Q1 2024 | Change (%) | | :--- | :--- | :--- | :--- | | Revenues | $8,344 | $10,663 | -22.4% | | Gross Profit | $4,354 | $6,662 | -34.3% | | Selling and marketing | $2,186 | $1,270 | +69.2% | | Research and development | $2,606 | $926 | +188.9% | | Net Income (Loss) | ($2,572) | $2,274 | -226.3% | - The decrease in revenue was primarily driven by a lower number of units sold to a large customer[106](index=106&type=chunk) - The increase in R&D expense was primarily due to significant lobbying costs related to billing code reimbursement, increased headcount, and product development[111](index=111&type=chunk) - Cash and cash equivalents decreased by **$3.0 million** during the quarter, from **$22.1 million** to **$19.1 million**[115](index=115&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=24&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) This section is not applicable for the reporting period - The company has indicated that this item is not applicable[129](index=129&type=chunk) [Controls and Procedures](index=25&type=section&id=Item%204.%20Controls%20and%20Procedures) As of March 31, 2025, management concluded that disclosure controls and procedures were effective, with no significant changes to internal control over financial reporting - Management, including the CEO and CFO, evaluated disclosure controls and procedures and concluded they were effective as of March 31, 2025[130](index=130&type=chunk) - No significant changes were made to internal control over financial reporting during the most recently completed fiscal quarter[131](index=131&type=chunk) PART II – Other Information [Legal Proceedings](index=26&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in ordinary course legal proceedings, with details on a Department of Justice investigation referenced in Note 6 - The company is involved in ordinary course legal proceedings and refers to Note 6, which details an ongoing DOJ investigation[134](index=134&type=chunk) [Risk Factors](index=26&type=section&id=Item%201A.%20Risk%20Factors) Investors are directed to the 2024 Annual Report for risk factors, as no new or amended risks are presented in this filing - For a discussion of risk factors, the report refers to Part I, Item 1A of the company's 2024 Annual Report[135](index=135&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=26&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales occurred in Q1 2025; the company repurchased 50,360 shares for $0.3 million under its $3 million stock repurchase program - There were no unregistered sales of securities during the three months ended March 31, 2025[136](index=136&type=chunk) Issuer Purchases of Equity Securities (Q1 2025) | Period | Total Shares Repurchased | Average Price Paid per Share | Approx. Dollar Value Remaining in Program | | :--- | :--- | :--- | :--- | | Jan 2025 | 0 | $— | $2,972,812 | | Feb 2025 | 50,360 | $5.90 | $2,672,816 | | Mar 2025 | 0 | $— | $2,672,816 | | **Total** | **50,360** | **$5.90** | | [Defaults Upon Senior Securities](index=26&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities during the period - None[141](index=141&type=chunk) [Mine Safety Disclosure](index=27&type=section&id=Item%204.%20Mine%20Safety%20Disclosure) This section is not applicable to the company - Not applicable[142](index=142&type=chunk) [Other Information](index=27&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted or terminated any Rule 10b5-1 trading plans during Q1 2025 - No directors or officers adopted or terminated any Rule 10b5-1 trading plans during the quarter[143](index=143&type=chunk) [Exhibits](index=27&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including CEO and CFO certifications and Inline XBRL documents - The exhibits filed include CEO and CFO certifications pursuant to Rule 13a-14(a) and 18 U.S.C. Section 1350, as well as Inline XBRL files[145](index=145&type=chunk)

Exhibit 99.1 ● Revenues were $8.3 million ● Net loss was $2.6 million, or $(0.16) per share ● Shipped 21 superficial radiotherapy (SRT) systems, including 15 to a large customer and one internationally ● Showcased SRT systems and several pre-commercial products at the 2025 Winter Clinical Dermatology Conference and at the 2025 American Academy of Dermatology (AAD) Annual Meeting, including hosting a highly successful event for customers and prospects First Quarter Financial Results Revenues were $8.3 millio ...

Group 1 - Sensus Healthcare, Inc. (SRTS) stock closed at $4.22, down 0.47% from the previous day, underperforming compared to the S&P 500's gain of 0.44% [1] - The stock has decreased by 7.22% over the past month, contrasting with the Medical sector's gain of 1.16% and the S&P 500's gain of 10.62% [1] Group 2 - The upcoming earnings report for Sensus Healthcare is scheduled for May 15, 2025, with projected earnings per share (EPS) of $0.04, indicating a 71.43% decrease year-over-year [2] - Revenue is expected to be $7.27 million, reflecting a 31.8% decline compared to the same quarter last year [2] Group 3 - For the annual period, Zacks Consensus Estimates predict earnings of $0.29 per share and revenue of $43.45 million, representing changes of -29.27% and +3.93% respectively from the previous year [3] Group 4 - Recent changes to analyst estimates for Sensus Healthcare reflect shifting short-term business dynamics, with positive revisions indicating a favorable outlook on the company's health and profitability [4] Group 5 - The Zacks Rank system, which incorporates estimate changes, currently ranks Sensus Healthcare at 4 (Sell), with the consensus EPS estimate remaining unchanged over the past month [6] Group 6 - Sensus Healthcare's Forward P/E ratio is 14.88, which is a discount compared to the industry's average Forward P/E of 25.35 [7] - The Medical - Instruments industry, part of the Medical sector, holds a Zacks Industry Rank of 84, placing it in the top 35% of over 250 industries [7]